(firstQuint)Satraplatin for Patients With Metastatic Breast Cancer (MBC).

 This is a Phase II open label, nonrandomized study for patients with metastatic breast cancer.

 WHAT IS SATRAPLATIN: Satraplatin is a member of the platinum-based class of chemotherapy drugs.

 Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies.

 Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

.

 Satraplatin for Patients With Metastatic Breast Cancer (MBC)@highlight

To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.

